$LYEL News

Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection

Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97%

Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update

Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress

Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances

Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)

Lyell Immunopharma Announces Participation in May Investor Conferences

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target